Abivax race — the field, a rising price tag, and why AZN can't be ruled out
Following on the AZN read-across: Soriot's FT interview ({MSG /ID 6A53155D0002B622284A0001 <GO>} lays out the exact demand backdrop — "nearly $20bn of sales" going generic after 2030 and only "halfway to a target of launching 20 new medicines by 2030" — that keeps AstraZeneca in the frame for a de-risked immunology asset. But AZN is the outsider on this list, not the favourite, and the price to play just went up.
The likely buyer field. Abivax has been a named takeover target since JPM in January, when Eli Lilly was reported to be eyeing a ~€15bn ($17.5bn) deal. The natural aggressors all have existing IBD/immunology muscle Abivax lacks:
- Eli Lilly — the named bidder; building out immunology and the most-cited suitor.
- AbbVie — the IBD franchise leader (Skyrizi/Rinvoq), managing Humira erosion; the obvious strategic consolidator.
- Johnson & Johnson — Stelara/Tremfya in IBD, with Stelara off patent; motivated to refill.
- Takeda — owns Entyvio, a leading IBD drug; the cleanest strategic fit, though more balance-sheet constrained.
- Sanofi / Merck / Roche — all acquisitive and pipeline-hungry (Merck notably chasing the Keytruda cliff).
- AstraZeneca — plausible but adjacent: UC/IBD sits next to, not inside, its R&I core. Capacity is a non-issue (a $20bn deal takes it to ~2.2x net debt/EBITDA, well within its rating), but it would be gate-crashing rather than defending turf.
The price tag has moved up, not down. The €15bn/$17.5bn January number now looks like a floor for three compounding reasons: obefazimod's Phase 3 maintenance data landed positive; the mid-year cancer-signal scare (stock -43% in early June) was largely walked back by end-June safety data (+36%); and — critically — Abivax just raised ~$920M to fund a solo US launch with runway to ~2029. That raise does two things to any bid: it adds cash to the equity bridge, and it removes the distressed-seller dynamic entirely. A buyer now has to pay a control premium over a company that has credibly said it doesn't need one. Net effect: the realistic take-out has drifted from ~$17.5bn toward $20bn+.
Why the premium holds — a quick scarcity check. The thing that makes obefazimod expensive is how rare its profile is: genuinely first-in-class mechanism (oral miR-124 enhancer), Phase 3 de-risked, in a market as big as UC + Crohn's (IBD is heading for ~$27–31bn by 2030). Scanning the late-stage biotech field for comparable "first-in-class + Phase 3 + IBD-scale TAM" assets, there aren't many:
- Revolution Medicines — the closest analogue on type: truly first-in-class (RAS(ON) inhibitors), Phase 3, huge oncology TAM — and itself the subject of a reported $28–32bn Merck approach, which is the read-across for how these scarce assets get priced.
- MoonLake (sonelokimab) — novel Nanobody format, Phase 3-positive in hidradenitis suppurativa/PsA; large immunology TAM but a smaller indication and not strictly a new mechanistic class (IL-17).
- Structure Therapeutics / Immunovant / Vera — big or broad TAMs, but each is best-in-class within an established class (oral GLP-1, FcRn, APRIL/BAFF) rather than first-in-class.
The takeaway: most large-TAM Phase 3 assets are differentiated entrants in crowded classes. A new-mechanism, de-risked, ~$25bn-market asset is genuinely scarce — which is exactly why Abivax commands the premium, why its own board feels able to go it alone, and why any acquirer (AZN included) has to pay up to be in the room.
Best, Laurent